Personally impacted by addiction and overdose throughout his life and losing several childhood friends, Collin decided to spend his career focused on challenging the status quo by developing innovative new solutions. During this process, he and his partners created ARMR Sciences with the mission of developing preventative and protective solutions for the addiction and overdose epidemic.

Prior to founding ARMR, Collin was the Senior Vice President of Corporate Development and Investor Relations at Mind Medicine Inc. (NASDAQ: MNMD), a clinical-stage biopharmaceutical company focused on pioneering addiction and mental health treatments. During his tenure at MindMed, he managed firm-wide capital markets strategy, laying the foundation for the company to go on to raise more than $250 million to support late-stage clinical trials. This work eventually led to MindMed receiving Breakthrough Therapy Designation from the U.S. Food & Drug Administration (FDA).

Before MindMed, Collin was responsible for researching and investing in innovative early-stage startups at a private family office. In this role, he worked with several venture-backed startups to guide them through complex financial strategies in private and public capital markets.

Earlier in his career, Collin worked as a Consultant for Tesla, Inc. (NASDAQ: TSLA), where he was responsible for identifying and executing emerging market growth strategies. He began his career as a consultant at Point72 Asset Management, a global multi-strategy asset manager.